{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-029792","form_type":"8-K","ticker":"LMAT","cik":"0001158895","company_name":"LEMAITRE VASCULAR INC","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.359029+00:00","generated_at":"2026-06-09T02:02:09.381274+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LeMaitre Q3 sales $47.4M (+21%); EPS $0.33; declares $0.14 dividend; guides Q4 $48-50M","bullets":["Q3 sales $47.4M (+21% YoY, +16% organic); net income $7.5M (+38%); diluted EPS $0.33 (+36%).","Gross margin 65.0% (+80 bps); operating income $9.2M (+49%); cash up $6.8M to $97.0M.","Q4 2023 guidance: sales $48-50M, EPS $0.34-0.38; full-year 2023 EPS $1.30-1.35 (+42% YoY).","Quarterly dividend $0.14/share, payable Nov 30 to shareholders of record Nov 16.","Leases for Burlington, MA headquarters extended to Dec 31, 2034 with escalating rent; no renewal options."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-029792","json":"https://secwatch.observer/filing/0001437749-23-029792.json","markdown":"https://secwatch.observer/filing/0001437749-23-029792.md","text":"https://secwatch.observer/filing/0001437749-23-029792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/0001437749-23-029792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/lmat20231101_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:02:09.381274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a776e15cc2d997807588ef83414098e8bfb40c0","claim":"LEMAITRE VASCULAR INC reported quarter ended September 30, 2023 results: revenue $47.4mm, net income $7.5mm, EPS $0.33. Guidance initiated.","evidence_excerpt":"of vascular devices, implants and services, today reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q3 2023 Financial Results ● Sales $47.4mm, +21% (+16% organic) vs. Q3 2022 ● Gross margin 65.0%, +80 bps ● Op. income $9.2mm, +49% ● Op. margin 19% ● Net income $7.5mm, +38% ● Earnings per diluted share $0.33, +36% ●","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/0001437749-23-029792-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"$47.4mm"},{"label":"Net income","value":"$7.5mm"},{"label":"EPS","value":"$0.33"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"2be45d7bf023748b51a6567c6c617bc2c8a49c01","claim":"LEMAITRE VASCULAR INC amended Amendments (effective 2023-10-18).","evidence_excerpt":"On October 18, 2023, LeMaitre Vascular, Inc. (the “Company”) entered into amendments (“Amendments”) to its leases for its headquarter properties located at 32-34 Third Avenue and 43, 53 and 63 Second Avenue in Burlington, Massachusetts.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/0001437749-23-029792-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"lease"},{"label":"Effective","value":"2023-10-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}